动态对比增强磁共振与标准神经导航磁共振在胶质瘤活检靶向选择中的前瞻性双盲评估
这项前瞻性双盲研究纳入28例疑似胶质瘤患者,比较基于T1W动态对比增强MRI(DCE-MRI)衍生Ktrans图的活检靶向选择与标准神经导航(3D FLAIR和CET1W)的选择效果。排除5例无Ktrans升高病例后,Ktrans靶向样本与参考全肿瘤诊断的一致性在WHO IV级和III/II级中均高于标准影像,但差异未达统计学显著;在非对比增强胶质瘤中,Ktrans靶向选择显著更准确。
要点
- Ktrans靶向活检样本与全肿瘤参考诊断一致性在WHO IV级为30/39 vs 标准11/20(p=0.08)。
- WHO III/II级一致性为12/13 vs 标准6/11(p=0.06),差异未达统计学显著。
- 在5例非对比增强胶质瘤中4例,Ktrans选择较标准技术显著更准确(10/12 vs 2/8,p=0.02)。
核心结论
- 若存在Ktrans升高,基于Ktrans的活检靶向在非对比增强胶质瘤中较仅基于CET1W和FLAIR加权图像的选择提供显著更多诊断性组织样本。
研究设计与样本
- 前瞻性双盲评估,28例疑似胶质瘤患者接受3.0 T MRI包括DCE-MRI和标准神经导航协议(3D FLAIR和CET1W数据集,钆布醇0.1 mmol/kg)。
- 排除5例无Ktrans升高病例后,每例由神经外科医生基于标准影像和神经放射科医生基于Ktrans独立选择2-6个活检靶点,由独立神经外科医生采集对应组织样本。
- 样本由对选择方式盲法的神经病理学家评估与全肿瘤切除参考诊断(67例WHO IV,24例WHO III和II)的诊断一致性。
主要发现
- Ktrans基于的样本靶点在90/91例中与标准技术样本靶点不同。
- Ktrans基于样本较标准影像基于样本可提取更多。
- Ktrans基于样本诊断与参考全肿瘤诊断一致性更频繁:WHO IV级30/39 vs 标准11/20(p=0.08);WHO III/II级12/13 vs 标准6/11(p=0.06)。
- 在4/5例非对比增强胶质瘤中,Ktrans基于选择显示较标准技术样本选择显著更准确(10/12 vs 2/8样本;p=0.02)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current biopsy planning based on contrast-enhanced T1W (CET1W) or FLAIR sequences frequently delivers biopsy samples that are not in concordance with the gross tumor diagnosis. This study investigates whether the quantitative information of transfer constant Ktrans maps derived from T1W dynamic contrast-enhanced MRI (DCE-MRI) can help enhance the quality of biopsy target selection in glioma. 28 patients with suspected glioma received MRI including DCE-MRI and a standard neuronavigation protocol of 3D FLAIR- and CET1W data sets (0.1 mmol/kg gadobutrol) at 3.0 T. After exclusion of five cases with no Ktrans-elevation, 2-6 biopsy targets were independently selected by a neurosurgeon (samples based on standard imaging) and a neuroradiologist (samples based on kinetic parameter Ktrans) per case and tissue samples corresponding to these targets were collected by a separate independent neurosurgeon. Standard technique and Ktrans-based samples were rated for diagnostic concordance with the gross tumor resection reference diagnosis (67 WHO IV; 24 WHO III and II) by a neuropathologist blinded for selection mode. Ktrans-based sample targets differed from standard technique sample targets in 90/91 cases. More Ktrans-based than standard imaging-based samples could be extracted. Diagnoses from Ktrans-based samples were more frequently concordant with the reference gross tumor diagnoses than those from standard imaging-based samples (WHO IV: 30/39 vs. 11/20; p = 0.08; WHO III/II: 12/13 vs. 6/11; p = 0.06). In 4/5 non-contrast-enhancing gliomas, Ktrans-based selection revealed significantly more accurate samples than standard technique sample-selection (10/12 vs. 2/8 samples; p = 0.02). If Ktrans elevation is present, Ktrans-based biopsy targeting provides significantly more diagnostic tissue samples in non-contrast-enhancing glioma than selection based on CET1W and FLAIR-weighted images alone.
引用
- Keil VC, Pintea B, Gielen GH, et al. Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits. J Neurooncol. 2017. PMID: 28425048. doi:10.1007/s11060-017-2424-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。